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Cost talk: protocol for a stepped-wedge
cluster randomized trial of an intervention
helping patients and urologic surgeons
discuss costs of care for slow-growing
prostate cancer during shared decisionmaking
Mary C. Politi1* , Rachel C. Forcino2, Katelyn Parrish1, Marie-Anne Durand2,3, A. James O’Malley2,4 and Glyn Elwyn2

Abstract
Background: Costs of care are important to patients making cancer treatment decisions, but clinicians often do
not feel prepared to discuss treatment costs. We aim to (1) assess the impact of a conversation-based decision aid
(Option Grid) containing cost information about slow-growing prostate cancer management options, combined
with urologic surgeon training, on the frequency and quality of patient-urologic surgeon cost conversations, and (2)
examine the impact of the decision aid and surgeon training on decision quality.
Methods: We will conduct a stepped-wedge cluster randomized trial in outpatient urology practices affiliated with
a large academic medical center in the USA. We will randomize five urologic surgeons to four intervention
sequences and enroll their patients with a first-time diagnosis of slow-growing prostate cancer independently at
each period. Primary outcomes include frequency of cost conversations, initiator of cost conversations, and whether
or not a referral is made to address costs. These outcomes will be collected by patient report (post-visit survey) and
by observation (audio-recorded clinic visits) with consent. Other outcomes include the following: patient-reported
decisional conflict post-visit and at 3-month follow-up, decision regret at 3-month follow-up, shared decisionmaking post-visit, communication post-visit, and financial toxicity post-visit and at 3-month follow-up; clinicianreported attitudes about shared decision-making before and after the study, and feasibility of sustained intervention
use. We will use hierarchical regression analysis to assess patient-level outcomes, including urologic surgeon as a
random effect to account for clustering of patient participants.
Discussion: This study evaluates a two-part intervention to improve cost discussions between urologic surgeons
and patients when deciding how to manage slow-growing prostate cancer. Establishing the effectiveness of the
strategy under study will allow for its replication in other clinical decision contexts.
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Background
Financial toxicity refers to patients’ distress resulting
from the costs of cancer care [1]. Direct and indirect
treatment costs contribute to financial toxicity among
people with cancer [2, 3]. Financial toxicity is associated
with both poorer clinical outcomes [1, 4, 5] and poorer
quality of life in cancer survivors [6, 7] and has an impact for many years after diagnosis [8]. Many patients
with cancer report financial toxicity [8]. Its prevalence
has made addressing the costs of care a priority for patients [9] and healthcare organizations [10, 11].
Patient-clinician discussions about treatment costs can
help lower costs of care and reduce financial toxicity [1].
Patients welcome opportunities to discuss treatment
costs with their clinicians [9, 12], but few patients and
clinicians engage in cost conversations in routine practice [13–15]. As a result, many patients with prostate
cancer pay more for their treatment than they expected
[16]. While clinicians acknowledge the importance of
addressing financial toxicity [17], they feel underprepared to initiate or lead cost conversations [13].
Preparing clinicians for cost discussions is an important component of reducing patients’ financial toxicity.
After addressing costs during treatment discussions, clinicians can seek support from other professionals, such
as social workers or financial navigators, to provide details about personal costs based on insurance and health
needs [18]. Referring the patient for additional advice is
a key outcome of initiating cost conversations.
To address the gap between guidelines, needs, and
practice, in this study, we will train urologic surgeons in
the use of a conversation-based decision aid containing
cost-related resources to discuss costs when engaging in
shared decision-making (SDM) for slow-growing (also
called low-risk) prostate cancer. We will examine the
resulting frequency and content of cost discussions between urologic surgeons and patients as they discuss this
preference-sensitive treatment decision in the context of
SDM. Results can provide insights into how to address
cost conversations during SDM about cancer care more
broadly.
Objectives
Aim 1

We aim to assess the impact of a conversation-based decision aid (Option Grid) containing cost information
about slow-growing prostate cancer management

options, combined with a brief training session for the
urologic surgeon, on the frequency and quality of
patient-urologic surgeon cost conversations. We will
measure frequency of cost conversations, initiator of cost
conversations, and whether or not a referral is made to
address costs. We hypothesize that:
1.1: Urologic surgeons assigned to training and use of
the decision aid will engage in more frequent cost
conversations than urologic surgeons in usual care.
1.2: Urologic surgeons assigned to training and use of
the decision aid will be more likely than patients to
initiate cost conversations. Patients will be more likely
than urologic surgeons to initiate cost conversations in
usual care.
1.3: Urologic surgeons assigned to training and use of
the decision aid will be more likely to make a referral
to address specific cost details than urologic surgeons
in usual care.
1.4 (exploratory): Patients of urologic surgeons assigned
to training and use of the decision aid will have lower
financial toxicity at three-month follow-up than patients of urologic surgeons in usual care.

Aim 2

We aim to examine the impact of the conversationbased decision aid and surgeon training on decision
quality, including measures of decisional conflict, decision regret, and shared decision-making. We hypothesize
that:
2.1: Patients of urologic surgeons assigned to training
and use of the decision aid will report less decisional
conflict, less decisional regret at three-month followup, and more SDM than patients in usual care.

Methods
Design

This study uses a stepped-wedge cluster-randomized
trial design (see Fig. 1) [19]. There are four sequences,
with at least one cluster (urologic surgeon) randomized
to each sequence. The fifth urologic surgeon will be
assigned to the second sequence in order to balance patient accrual to the intervention and control arms. There
are five periods, each lasting 3 months, for a total study
duration of approximately 15 months. Independent
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Fig. 1 Study overview

eligible patients will be enrolled at each period within a
cluster (urologic surgeon).
We clustered intervention assignment at the urologic
surgeon level because the intervention includes urologic
surgeon training and is designed to impact clinical communication patterns, which are reflected in the study
outcomes. This clustering approach will minimize the
likelihood of contamination between study arms that
could occur with patient-level randomization.
The staggered assignment of participating urologic
surgeons to the intervention arm has several advantages.
The stepped-wedge design allows more surgeons to
undergo training in use of the decision aid intervention
than would a parallel trial design with a usual care control arm. This is an advantage in the context of strong
interest in learning about decision aids in the participating study setting paired with evidence that decision aids
improve patient-centered care [20]. Additionally, the
staggered timing of surgeon training will facilitate its
scheduling within busy clinician timetables. This improves overall study feasibility while ensuring a consistent intervention dose for all participating surgeons.
Setting

We will conduct this study in outpatient practices affiliated with a large academic medical center. These participating practices are located in a single metropolitan area
in the Midwest region of the USA. Decision aids were
not routinely used in the participating practices prior to
study participation.
Participants
Included urologic surgeons

We will recruit five urologic surgeons who routinely discuss management options for slow-growing prostate
cancer with patients.
Included patients

We will recruit up to 200 patient participants based on
projected volume of eligible patients during each period.

Eligible patients include adults visiting a participating
urologic surgeon to discuss management options for a
first-time diagnosis of slow-growing prostate cancer.
Slow-growing prostate cancer diagnoses will initially be
defined by a Gleason score of 6 or 7 (3 + 4) and/or
prostate-specific antigen (PSA) level less than 10 ng/ml,
and/or as confirmed by a surgeon’s referral prior to patient recruitment. Eligible patient visits may occur inperson or by telehealth. We will exclude patients who
cannot give informed consent due to cognitive or emotional barriers, and those who are discussing recurrent
or ongoing prostate cancer management. Patients seen
in these practices are from urban, suburban, and rural
settings (approximately 14% from rural settings and approximately 25% from a medically underserved area). Patients in these practices are racially diverse, with
approximately 20% identifying as Black or African
American, 3% identifying as Hispanic of any race, and
4% identifying as two or more races.
Intervention

This study tests a two-part intervention: (1) use of an
Option Grid conversation-based decision aid by urologic
surgeons and patients during their first consultation
about managing slow-growing prostate cancer and (2)
brief urologic surgeon training in shared decisionmaking, patient-facing financial resources, and best practices for conversation-based decision aid use.
Option Grid conversation-based decision aid with cost
information

The Option Grid decision aid is a table with side-by-side
comparisons of management options for slow-growing
prostate cancer (specified in Table 1), organized as responses to patients’ frequently asked questions [21].
Written at a sixth grade reading level, the grid was developed, tested, and validated using a systematic process
including evidence summarization and stakeholder input
[21–23]. This type of decision aid is not designed to be
comprehensive,
but
to
supplement
clinicians’
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Table 1 Relative cost information added to the Slow-Growing Prostate Cancer Option Grid
Option

Included relative cost information

Monitor with tests

Costs include testing at least once a year. Check your insurance for your exact costs.
$-$$

Prostatectomy

Costs include surgery and hospital stay, up to 3 days. Check your insurance for your exact
costs.
$$$

Radiation (external beam radiation therapy or
brachytherapy)

Check your insurance for your exact costs.
External beam radiation: $$$
Brachytherapy: $$-$$$

Included cost resources
Health insurance can help cover some of your care costs. Whatever type of insurance you have, you want to get the most from your plan. You
should call your plan to find out things like:
• Does my plan cover the care I need?
• Are the hospital and doctors who will be treating me part of my plan’s network?
• Does my plan cover the facility fee? If so, how much of the fee is covered?
• Do I need to be pre-approved by the insurance company before getting this care?
• How much of my deductible have I met? How much of my deductible is left before I meet it?
• What will be the copay or coinsurance for the treatment I need?
In many cancer centers, social workers or navigators can help patients find information about costs or apply for help paying your bills. They can also
help if you need a way to get to and from treatment, short-term housing, or have problems with your job because of your care.
For more information or to reach a social worker at [cancer center name], you can call [phone number]. This website also has resources for patients
at [cancer center name], including how to apply for more help paying your bills. [Web address for cancer center’s patient support services]

explanations [24]. For this study, we have added two
types of cost information to the Option Grid: (1) general descriptions of relative costs [25] for each treatment/management option (see Tables 1 and 2) a list
of general and local resources for navigating cancer
care costs. Participating urologic surgeons will deliver
the Option Grid intervention at the individual patient
level.
Option Grid training

At the start of the study, urologic surgeons will be
trained in the study protocol. At the start of their active
arm assignment, each surgeon will complete a survey
about their attitudes relating to SDM and will be trained
in use of the Option Grid, including discussing costs
with patients. Option Grid training will (1) present a
model of SDM [36] and best practices for use of the Option Grid; (2) share details about incorporating cost discussions into SDM; (3) provide each surgeon with a list
of cost-related resources and referrals for patients, including ways to lower out-of-pocket costs; and (4) include a mock patient simulation to allow the urologic
surgeon to practice using the intervention. The study’s
principal investigator (MCP) and co-principal investigator (GE) will deliver the Option Grid training at the
cluster level.
Outcomes
Primary outcomes

We will measure the frequency of cost conversations,
initiator of cost conversations, and whether or not a
referral is made to address costs. We will collect
these primary outcomes by patient report from all

participating patients in a questionnaire completed
immediately post-visit (or shortly after a telehealth
visit).
We will also use an existing observer checklist [14]
to assess these outcomes for participating patients
who consent to audio-recording their clinic visits. We
will use Hunter et al.’s approach to defining a cost
discussion: “any mention of the patient’s out-ofpocket expenses or insurance coverage for a past,
present, or potential health care service” [26]. For example, any mention of costs or insurance coverage
for primary surgery, radiation, imaging, as well as indirect costs of care such as time off work, transportation, recovery time, will be documented and included
in our analyses. If direct or indirect costs are mentioned per Hunter’s definition [26], we will indicate
that costs were discussed during the consultation. If
there are two mentions of cost in one transcript, with
a different topic in between, the mentions will be
coded as two cost discussions. If costs are discussed
at all, the subsequent items (length of time of the
cost conversation, number of times cost was discussed, who initiated the cost discussion, content of
cost discussions, whether a referral is made to address
costs) will then be evaluated. We will document references to the Option Grid to examine whether the
Option Grid directly prompted the cost conversation.
Because we do not expect surgeons to know specific
details about treatment costs, the checklist also includes an item to measure whether a referral is made
to address more detail about costs. We will document
to whom a referral is made (navigator, social worker,
outside resource).
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Table 2 Study data summary
Domain (measure)

Source

Timing

Frequency of cost conversations (adapted Politi [14]/Hunter [26] checklist)

Patient report;
observation

Immediately post-visit

Initiator of cost conversations (adapted Politi [14]/Hunter [26] checklist)

Patient report;
observation

Immediately post-visit

Referral to address costs (adapted Politi [14]/Hunter [26] checklist)

Patient report;
observation

Immediately post-visit

Patient report

Immediately post-visit

Primary outcomes

Secondary outcomes
Shared decision-making (collaboRATE [27])
Effort made to compare costs of treatment options

Patient report

Immediately post-visit

Clinical communication (CAHPS communication composite [28])

Patient report

Immediately post-visit

Decisional conflict (SURE [29])

Patient report

Immediately post-visit, 3 months postvisit

Decision regret (Decision Regret Scale [30])

Patient report

3 months post-visit

Patient report

Immediately post visit; 3 months postvisit

Exploratory outcomes
Financial toxicity (COST [31, 32])
Implementation and acceptability outcomes
Attitudes toward SDM (Continuing Professional Development Reaction Scale [33]) Clinician report

Beginning of study period; end of
study period

Feasibility of sustained cost conversations and Option Grid use

Clinician report

End of study period

Acceptability of cost conversations and Option Grid use (adapted Ottawa
Acceptability Scale [34])

Clinician report

End of study period

Treatment choice

Patient report

Immediately post-visit

Treatment received

Electronic health
record

3 months post-visit

Health literacy (Single-Item Literacy Screener [35])

Patient report

Immediately post-visit

Patients’ other (comorbid) health conditions

Electronic health
record

Immediately post-visit

Patients’ demographic characteristics

Patient report

Immediately post-visit

Other data

Secondary outcomes

Patient-reported Within 24 h after the clinic visit, we
will collect the following patient-reported outcomes: the
SURE measure of decisional conflict [29], the collaboRATE measure of SDM [27], a single item added to collaboRATE to assess effort to compare costs of
treatment, the CAHPS measure of communication quality [28], and the COST measure of financial toxicity [31,
32]. Financial toxicity will be an exploratory outcome.
At 3-month follow-up, we will collect the following
patient-reported outcomes: the SURE measure of decisional conflict [29], the decision regret scale [30], and
the COST measure of financial toxicity [31, 32]. Financial toxicity will be an exploratory outcome.
Clinician-reported Participating urologic surgeons will
complete a 12-item measure of SDM perceptions [33] at

the start of their arm assignment and again at the end of
the study period. Each study urologic surgeon will also
complete an adaptation of the Ottawa Acceptability
Scale [34] and survey items about feasibility of routine
Option Grid use at the end of the study period.
Table 2 summarizes all study measurement, including
outcomes and planned covariates.
Randomization

We will randomly allocate clusters (urologic surgeons)
to the intervention sequences with a simple
randomization approach (i.e., no blocking, stratification,
or other constraints) using R statistical software.
Randomization will take place after urologic surgeon recruitment is complete; both participating urologic surgeons and the study team are therefore blinded to
allocation until after urologic surgeon recruitment. The
study coordinator (KP) will enroll clusters (urologic
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surgeons) to the study. The study statistician (AJO),
blinded to the identity of each cluster, will generate the
randomization schedule and assign cluster IDs to
sequences.
Eligible patients will be recruited continuously
throughout the study period; the study coordinator
(KP) will identify eligible patients and seek their informed consent to participate during both control
and intervention periods. In order to manage logistics
of implementing the intervention and recruiting patient participants, the principal investigators (MCP,
GE), study coordinator (KP), and participating urologic surgeons will learn the allocated sequence assignments immediately post-randomization. Patients
will not be informed of their study arm allocation
during the recruitment process, but will not be
blinded as they will observe whether or not they receive the Option Grid intervention at the time of
their visit. Other members of the study team, including those analyzing results, will remain blinded to
cluster sequence allocation throughout the study.

Procedures

Figure 2 summarizes study enrollment, interventions,
and assessments.

Fig. 2 Schedule of enrollment, interventions, and assessments
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Stakeholder advisory group

A stakeholder advisory group comprising patients, clinicians, and prostate cancer advocates has informed our
study design, outcomes, and procedures. This group will
meet every 1 to 2 months throughout the study period
to co-design study materials, monitor study progress,
and troubleshoot problems where necessary. We compensate these stakeholder partners at a rate that reflects
their substantial expertise and commitment.
Recruitment

Clinician recruitment Urologic surgeons who wish to
participate will register their interest with the urology division chief, who will share their contact details with the principal investigator (MCP) to facilitate enrollment. In the
weeks prior to the start of the study period, the study coordinator (KP) will seek written informed consent from interested and eligible urologic surgeons by phone and/or email.
Patient recruitment We will recruit patient participants
from July 2020 through September 2021. The study coordinator will identify potentially eligible patients with
upcoming clinic visits using clinic schedules, electronic
health records, contact with clinicians, and contact with
clinic coordinators, then confirm eligibility with the
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patient’s urologic surgeon. The study coordinator will
retrieve phone numbers for eligible patients from the
electronic health record. To assess interest in participating, the study coordinator will contact each eligible patient by phone before their scheduled visit, but after the
care team has communicated a prostate cancer diagnosis
to the patient. To reduce risk of selection bias due to
unblinded treatment allocation, the study coordinator
will approach all eligible patients, defined as men with
prostate cancer who have a Gleason 6 or 7 and/or PSA
less than or equal to 10 ng/ml, or as referred by a surgeon whose clinical expertise confirms that the individual is eligible for the options in the Option Grid
intervention. If the eligible patient is interested in participating, the study coordinator will document informed
consent over the phone, electronically as a waiver of
written consent for those who agree to be emailed, or
in-person when the patient arrives for the clinic visit.
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data will be stored in REDCap and response modality
will be recorded. Study staff will make up to five attempts to contact patient participants for response to
each survey.
After completion of the first post-visit questionnaire,
study staff will mail patient participants a $15 gift card.
After completion of the second questionnaire at 3month follow-up, study staff will mail patient participants a $5 gift card.
Clinician-reported data For each set of clinicianreported outcomes, the study coordinator will email a
link to an online survey hosted in REDCap to each participating urologic surgeon. The study team will send
email reminders as needed until responses are collected
from each participating urologic surgeon. Upon completion of all study procedures, the study team will provide
a $50 gift card to each participating urologic surgeon at
the end of the study period.

Data collection
Intervention implementation

Observational data For participating patients who agree
during the study consent process to audio-recording of
their in-person clinic visits, the study coordinator will
start a digital recorder when the patient enters the exam
room and return to collect the recorder at the end of the
clinic visit. Where participating patients agree to audiorecording of their virtual visits, audio-recordings will be
captured by the urologic surgeon through Zoom or
other HIPAA-compliant telemedicine software and subsequently transferred securely to the study coordinator.
Audio-recordings will be transcribed verbatim for analysis. Two members of the study team will independently
review each transcript and apply the observer checklist
[14, 26] to identify frequency and initiator of cost conversations and frequency of referrals to address costs.
At the time of patient enrollment, study staff will review the electronic health record to determine whether
or not the participant has been diagnosed with each of
the 20 most common and costly health conditions, as
described in the Medical Panel Expenditure Survey [37–
39], and record those comorbidities in the study’s Research Electronic Data Capture database (REDCap). At
3-month follow-up, study staff will collect the patient’s
received treatment (if any) from the electronic health
record and record that information in REDCap.
Patient-reported data We will administer post-visit patient questionnaires at two timepoints: immediately after
the clinic visit and 3 months after the clinic visit. At
both timepoints, study staff will collect patient-reported
data by emailed link to an online survey form hosted in
REDCap or by standardized telephone interview, depending on participant preference. All questionnaire

Option Grid training At the start of the study period,
while all urologic surgeons are allocated to the usual
care control condition, study staff will schedule an Option Grid training session with each urologic surgeon to
be held at the beginning of his or her designated intervention period. Training sessions will be led by the principal investigators (MCP and GE) and held in-person
and/or by Zoom videoconference.
Option Grid delivery Participating urologic surgeons
will deliver the Option Grid to all their patients who face
a management decision for slow-growing prostate cancer. Some urologic surgeons will direct patients to access
the Option Grid through a secure web link prior to their
visits, while others will send the Option Grid to patients
by postal mail or through the online patient portal. At
the time of patient enrollment, the study coordinator
will confirm that each participating patient has received
the Option Grid from their care team. If a participating
patient has not received the Option Grid, study staff will
provide it by email or postal mail prior to the patient’s
visit.
Sample size

We assume given the study timeline and projected patient volumes that it is feasible to recruit up to 50 patients from each of the five participating urologic
surgeons, to target a total of 200 patient participants.
Due to the novelty of our shared decision-making intervention intended to promote cost conversations in cancer care, limited data were available to inform the
assumed ICC [14]. Based on the unmeasured clinician-
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level variability observed in other studies using similar
interventions to study different outcomes, we conservatively assumed a relatively large ICC value of 0.05. Under
these assumptions, and assuming an intraclass correlation coefficient of 0.05 for our primary outcome, the
design effect of the stepped-wedge design equals 3.12,
making the effective sample 32 per intervention group;
this is the equivalent sample-size under a design in
which there is no clustering of patients within surgeons
[40].
In relation to Aim 1 and our primary research questions, prior research demonstrates that surgeons who
used an encounter decision aid about early-stage breast
cancer surgery with comparative cost information were
far more likely to engage in cost conversations compared
to those using a decision aid without cost information or
those in usual care (66.7% versus 33.3%) [14]. Surgeons
in the cost information decision aid group were also
more likely to initiate these conversations compared to
those in the non-cost information decision aid group
(86.4% versus 34.1%) [14]. We estimated power directly
for a stepped-wedge design. A requirement for performing this calculation is supplying the between-cluster variance. We estimated this quantity by solving for its value
given the specified ICC of 0.05 and the within-cluster
variance of a Bernoulli (binary-valued) random variable,
whose mean equals the average value of the assumed
probabilities of the outcomes for the two comparison
groups (0.5, the most conservative value we could assume). The resulting power for a two-sided test was estimated to be 0.804. A projected sample size of 200 is
therefore sufficient to answer our primary research
questions.
Our two-step approach to the included sample size
calculation involved mathematical approximations,
which may reduce its reliability. While the alternate
method of calculating power using a simulation model
may have improved the reliability of our sample size calculation in some ways, that approach would require additional assumptions about the effects of time and other
covariates on the basis of little available empirical evidence, which may also reduce overall reliability. Therefore, we favor the simpler calculation.
Because of the low-risk nature of the intervention with
regard to likelihood and magnitude of potential harms,
we do not plan to conduct interim analyses and have
not established stopping guidelines.
Analysis

We will perform unadjusted bivariate comparisons of
outcomes and predictors across intervention groups
using t tests for continuous variables and chi-square
tests for categorical variables. We will also conduct analysis adjusting for patient demographic characteristics,

Page 8 of 10

patient clinical characteristics, and the time period when
the patient began follow-up. We will use logistic regression to model the Aim 1 primary outcome of whether or
not a cost conversation occurred. In Aim 2, we will use
linear regression to analyze outcomes with multi-level
scales (e.g., decision regret scale [30]) and logistic regression to analyze binary outcome measures (e.g., collaboRATE [41]). To account for clustering of patient
participants by urologic surgeon, we will estimate hierarchical models with urologic surgeon random effects.
Let Yijt denote an outcome measured on the ith patient
of the jth surgeon at time t and OGjt indicate whether
surgeon j has transitioned from usual care to the Option
Grid (OG) by time period t. To lessen the reliance on
the random assignment of surgeons to step times to balance any changes across time between the intervention
groups, we adjust for the time period when the patient
began follow-up, patient demographic and patient clinical characteristics. Adjustment for time period will be
enabled by including indicator variables for time periods
2 through 5 (making time period 1 the excluded category) with effects denoted by {λt}=t = 2 : 5 while all other
patient-level variables will be included in a vector of covariates, denoted Xijt. Therefore, the model for the Aim
1 analysis and those outcomes modeled as binary random variables in Aim 2 has the form

logit Pr Y ijt ¼ 1 θ j ¼ β0 þ β1 OGjt þ β2 X ijt
þ λt þ θ j
ð1Þ
while the model for those outcomes modeled as continuous variables in Aim 2 has the form
Y ijt ¼ β0 þ β1 OGjt þ β2 X ijt þ λt þ θ j þ εijt

ð2Þ

where for both models θj is a random effect specific to
surgeon j and for the linear regression model ∈ijt is an
idiosyncratic error term. The surgeon random effects
and the error terms are assumed to be independent normally distributed random variables with unknown variance. Because 5 surgeons is a small number of units in
which to estimate a random effect, as a sensitivity analysis we will estimate the generalized estimating equation
alternative to these mixed effect models. We will favor
the approach that yields the more conservative results.
We will check for outliers and missing data. If there is
extensive missing data, we will use one of the following
remedies: (1) inverse-probability weighting if there is a
single form of missing data (e.g., only the outcome is
missing) or (2) multiple imputation if missingness occurs
sporadically across the outcomes and predictors. Analyses will follow the intention to treat principle. Where
required to make the skewed distribution of a variable
more
symmetric,
we
will
employ
variable
transformation.
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Discussion
This study evaluates a strategy to improve the frequency
and content of cost conversations between urologic surgeons and patients in preference sensitive decisions
about managing slow-growing prostate cancer. This research fills an important gap, as patients and professional organizations alike prioritize cost conversations
[9–12] but urologic surgeons can feel ill-equipped to initiate them [17]. Establishing the effectiveness of the
strategy under study is an important first step to replicating and/or adapting this approach to other clinical
decision contexts.
Practical issues in performing the study

COVID-19 has impacted clinical research worldwide,
with many non-urgent healthcare visits canceled,
postponed, or moved to a telehealth format in earlymid 2020. These changes allowed for a lower risk of
viral spread within healthcare facilities while directing
healthcare resources to COVID-19 treatment. As
COVID-19 infection counts stabilize, eligible patient
volumes are beginning to return to pre-pandemic
levels at the participating study setting. However, a
second wave of the virus during the study period
could limit our ability to recruit patient participants
and meet accrual targets according to our planned
timeline. Our inclusion of telehealth visits in this
study has the potential to mitigate a slowdown of inperson patient recruitment; however, it can complicate the previously planned in-person procedures. We
will document the number of patients seen via telehealth and in-person, and we will explore the potential impact of telehealth on outcomes.
The 2-year study timeline could limit our ability to assess outcomes at long term follow-up. As most active
surveillance costs do not accrue immediately, financial
toxicity data reported by patients on active surveillance
at 3-month follow-up may not be comprehensive; we
have therefore included financial toxicity as an exploratory outcome in this study.
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